The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Enzalutamide activity in patients with metastatic castration resistant prostate cancer (mCRPC) previously responding to antiandrogen withdrawal syndrome (AWS): A preliminary report.
Sergio Bracarda
Consultant or Advisory Role - Astellas Pharma; Bayer; Janssen Pharmaceutical ; Sanofi
Honoraria - Astellas Pharma; Bayer; Janssen Pharmaceutical ; Sanofi
Giuseppe Procopio
Consultant or Advisory Role - Bayer; Janssen Pharmaceutical
Honoraria - Bayer; Janssen Pharmaceutical
Daniele Alesini
No relevant relationships to disclose
Francesco Grillone
No relevant relationships to disclose
Francesco Massari
No relevant relationships to disclose
Alberto Zaniboni
No relevant relationships to disclose
Rodolfo Mattioli
No relevant relationships to disclose
Sebastiano Buti
No relevant relationships to disclose
Enrico Garanzini
No relevant relationships to disclose
Michele Sisani
No relevant relationships to disclose
Alketa Hamzaj
No relevant relationships to disclose
Amelia Altavilla
No relevant relationships to disclose
Verena De Angelis
No relevant relationships to disclose